Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 68
- Registration Number
- NCT05755386
- Locations
- ๐บ๐ธ
Ronald Reagan UCLA Medical Center UCLA Connie Frank Clinic, Los Angeles, California, United States
๐บ๐ธUniv Cali Irvine ALS Neuromuscular Tustin, Orange, California, United States
๐บ๐ธUCSF Main Centre, San Francisco, California, United States
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT05753592
- Locations
- ๐ญ๐บ
Novartis Investigative Site, Miskolc, Baz, Hungary
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 327
- Registration Number
- NCT05750628
- Locations
- ๐บ๐ฌ
Novartis Investigative Site, Kampala, Uganda
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14000
- Registration Number
- NCT05739383
- Locations
- ๐บ๐ธ
Clinical Research Advantage Fiel Family and Sports Med, PC, Tempe, Arizona, United States
๐บ๐ธCharles R Drew University of Medicine and Science, Los Angeles, California, United States
๐บ๐ธZenith Clinical Research Clinical Research, Hollywood, Florida, United States
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05739942
- Locations
- ๐บ๐ธ
University of Colorado Denver, Aurora, Colorado, United States
๐บ๐ธUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
๐บ๐ธUni of Utah Huntsman Cancer Inst, Salt Lake City, Utah, United States
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 222
- Registration Number
- NCT05734053
- Locations
- ๐ฉ๐ช
Novartis Investigative Site, Wuerzburg, Germany
The Belgian REAL (BE.REAL) Registry
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT05726838
- Locations
- ๐ง๐ช
Novartis Investigative Site, Yvoir, Belgium
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- Conditions
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT05722522
- Locations
- ๐บ๐ธ
Healthy Life Research, Miami, Florida, United States
๐บ๐ธMillennium Clinical Trials, Westlake Village, California, United States
๐บ๐ธIntegral Rheumatology and Immunology Specialists IRIS, Plantation, Florida, United States
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 618
- Registration Number
- NCT05714371
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Post Approval Commitment Study on Tabrectaยฎ (Capmatinib) in South Korea
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT05703516
- Locations
- ๐ฐ๐ท
Novartis Investigative Site, Seoul, Korea, Republic of